Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR Alpha Beta T-Cell and CD19 B-Cell Depletion for Haploidentical HCT in PID and Metabolic Disorders
NCT04414046Phase 2Recruiting
- Sponsor
- Johns Hopkins All Children's Hospital
- Start
- Jul 2020
- Primary completion
- Jun 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in primary immunodeficiency (PI) and histiocytic disorder, sponsored by Johns Hopkins All Children's Hospital. Primary endpoint: Incidence of successful donor engraftment at 100 days. Started Jul 2020; status: recruiting.
02
Conditions
primary immunodeficiency (PI)histiocytic disorder
Beyond the preview
Go deeper on NCT04414046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04414046.